

Taking ARVs

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)

GENERIC NAME	OTHER NAMES [BRAND NAME]*	DOSAGE (ADULTS)**	HOW TO TAKE	SIDE EFFECTS	CONTRAINDICATION S
<u>abacavir</u>	abacavir sulfate, ABC [Ziagen]	Prior to initiating therapy, test for the HLA-B*5701 allele. 600 mg by mouth daily, taken as either (1) 300 mg tablet twice daily or (2) 300 mg tablets once daily	Take with or without food.	Drug hypersensitivity, nausea, headaches, malaise, fatigue, sleep disorders	Abacavir is contraindicated in people who have the HLA-B*5701 allele, people with previous hypersensitivity reaction to abacavir, and people who have moderate or severe hepatic impairment.

 $\underline{\mathsf{emtricitabine}}$

FTC [Emtriva] Prior to or when initiating therapy, test for hepatitis B virus infection.

200 mg by mouth daily, taken as (1) 200 mg capsule once daily Take with or without food.

Headaches, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, weakness, increased cough, nasal congestion

Emtricitabine is contraindicated in people with previous hypersensitivity reaction to emtricitabine.

Prior to or when initiating therapy, test Lamivudine is contraindicated in for hepatitis B virus infection. Headaches, nausea, people with previous 3TC Take with or 300 mg by mouth daily, <u>lamivudine</u> malaise, fatigue, nasal hypersensitivity reaction to [Epivir] without food. taken as either (1) 150 congestion, diarrhea, cough lamivudine. mg tablet twice daily or (1) 300 mg tablet once daily tenofovir Tenofovir AF is a component of many HIV combination medications (see below). tenofovir AF, TAF For HIV treatment, 25 alafenamide Tenofovir AF is also used to treat hepatitis B virus and is indicated for the treatment [Vemlidy] mg by mouth once daily of chronic hepatitis B virus infection in adults with compensated liver disease. fumarate

tenofovir disoproxil fumarate

tenofovir DF, TDF [Viread] Prior to or when initiating therapy, test for hepatitis B virus infection.
300 mg by mouth daily, taken as (1) 300 mg

tablet once daily

Take with or without food.

Rash, diarrhea, nausea, headaches, pain, depression, weakness, decrease in bone mineral density

None

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)***

GENERIC NAME	OTHER NAMES [BRAND NAME]*	DOSAGE (ADULTS)**	HOW TO TAKE	SIDE EFFECTS	CONTRAINDICATIONS
<u>doravirine</u>	DOR [Pifeltro]	100 mg by mouth daily, taken as (1) 100 mg tablet once daily	Take with or without food.	Nausea, dizziness, headaches, fatigue, diarrhea, abdominal pain, abnormal dreams	Co-administration is contraindicated with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of doravirine.

<u>efavirenz</u>	EFV [Sustiva]	600 mg by mouth daily, taken as (1) 600 mg tablet once daily	Take on an empty stomach, preferably at bedtime.	Impaired concentration, abnormal dreams, rash, dizziness, nausea, headaches, fatigue, insomnia, vomiting	people with previous hypersensitivity reaction to efavirenz and when co- administered with elbasvir/grazoprevir.
<u>etravirine</u>	ETR [Intelence]	400 mg by mouth daily, taken as either (1) 200 mg tablet twice daily or (2) 100 mg tablets twice daily		Rash, peripheral neuropathy	None
rilpivirine	rilpivirine hcl, RPV [Edurant]	25 mg daily, taken as (1) 25 mg tablet once daily	Take with food.	Depressive disorders, headaches, insomnia, rash	Co-administration is contraindicated with drugs where significant decreases in rilpivirine plasma concentrations may occur, which may result in loss of virologic response and possible resistance and cross-resistance.

Efavirenz is contraindicated in

PROTEASE INHIBITORS (PIS)***

GENERIC NAME	OTHER NAMES [BRAND NAME]*	DOSAGE (ADULTS)**	HOW TO TAKE	SIDE EFFECTS	CONTRAINDICATIONS
-----------------	------------------------------	-------------------	-------------	--------------	-------------------

Prior to or when initiating therapy, test for renal function and in people with underlying liver disease, test for atazanavir sulfate, ATV 400 mg by mouth daily, [Reyataz] taken as (2) 200 mg

tablet once daily

liver disease, test for hepatic function.
400 mg by mouth daily, Take with food. taken as (2) 200 mg tablets once daily fl taking with ritonavir:
300 mg by mouth daily, taken as (1) 300 mg ticterus, rash, headaches, abdominal pain, vomiting, insomnia, peripheral neurologic symptoms, dizziness, myalgia, diarrhea, depression, fever

Atazanavir is contraindicated in people with previous hypersensitivity reaction to any of the components. Co-administration is contraindicated with alfuzosin, amiodarone (if co-administered with ritonavir), quinidine (if coadministered with ritonavir), triazolam, orally administered midazolam, ergot derivatives, rifampin, irinotecan, lurasidone (if co-administered with ritonavir), lovastatin, simvastatin, lomitapide, indinavir, cisapride, pimozide, St. John's wort, nevirapine, elbasvir/grazoprevir, glecaprevir/ pibrentasvir, and sildenafil.

darunavir

atazanavir

darunavir ethanolate, DRV [Prezista] Prior to or when initiating therapy, test for hepatic function and perform genotypic and/or phenotypic testing to assess drug susceptibility to HIV. Take with ritonavir: 800 mg by mouth daily, taken as (1) 800 mg tablet once daily

Take with food.

Diarrhea, nausea, rash, headaches, abdominal pain, vomiting

Nausea, jaundice/scleral

Co-administration is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index).

GENERIC NAME	OTHER NAMES [BRAND NAME]*	DOSAGE (ADULTS)**	HOW TO TAKE	SIDE EFFECTS	CONTRAINDICATIONS
fostemsavir	fostemsavir tromethamine, FTR [Rukobia]	1,200 mg by mouth daily, taken as (1) 600 mg tablet twice daily	Take with or without food.	Nausea, diarrhea, headaches, abdominal pain, indigestion, fatigue, rash	Fostemsavir is contraindicated in people with previous hypersensitivity reaction to fostemsavir or any components of the product.Co-administration is contraindicated with strong cytochrome P450 (CYP)3A inducers as significant decreases in fostemsavir plasma concentrations may occur, which may result in loss of virologic response.
ibalizumab-uiyk	ibalizumab, IBA [Trogarzo]	Single loading dose: 1 intravenous infusion of 2,000 mg (administered by a healthcare provider)Maintenance dose: 1 intravenous infusion of 800 mg every 2 weeks (administered by a healthcare provider)	Take with or without food.	Diarrhea, dizziness, nausea, rash	Ibalizumab-uiyk is contraindicated in people with previous hypersensitivity reaction to ibalizumab-uiyk or any components of the product.
maraviroc	MVC [Selzentry]	Prior to initiating therapy, test for hepatic function and for CCR5 tropism using a highly sensitive tropism assay. If taking with potent CYP3A inhibitors: 300 mg by mouth daily, taken as (1) 150 mg tablet twice daily If taking with NRTIs and other drugs that are not potent CYP3A inhibitors or CYP3A inducers: 1,200 mg by mouth daily, taken as (2) 300 mg tablets twice daily If taking with noninteracting medications: 600 mg by mouth daily, taken as (1) 300 mg tablet twice daily	Take with or without food.	Upper respiratory tract infections, cough, fever, rash, dizziness, flatulence, bloating	Maraviroc is contraindicated in patients with severe renal impairment or end-stage renal disease (ESRD) who are concomitantly taking potent CYP3A inhibitors or inducers.

INTEGRASE INHIBITORS

GENERIC NAME	OTHER NAMES [BRAND NAME]*	DOSAGE (ADULTS)**	HOW TO TAKE	SIDE EFFECTS	CONTRAINDICATIONS
cabotegravir	cabotegravir sodium, CAB [Vocabria]	Take with rilpivirine: 30 mg by mouth daily, taken as (1) 30 mg tablet once daily	Take with food.	Headaches, nausea, abnormal dreams, anxiety, insomnia	Cabotegravir is contraindicated in people with previous hypersensitivity reaction to cabotegravir.Co-administration is contraindicated with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, and rifapentine.

<u>dolutegravir</u>	dolutegravir sodium, DTG [Tivicay,Tivicay PD]	Prior to initiating therapy, test for pregnancy in people of childbearing potential. Take with rilpivirine: 50 mg by mouth daily, taken as (1) 50 mg tablet once daily	Take with or without food.	Insomnia, fatigue, headaches	Dolutegravir is contraindicated in people with previous hypersensitivity reaction to dolutegravir.Co-administration is contraindicated with dofetilide.
elvitegravir	[Vitekta]		by Gilead Sciences in 2017. on medications: Genvoya and		
raltegravir	raltegravir potassium, RAL [Isentress, Isentress HD]	1,200 mg by mouth daily, taken as (2) 600 mg tablets once daily OR 800 mg by mouth daily, taken as (1) 400 mg tablet twice daily	Take with or without food.	Insomnia, headaches, dizziness, nausea, fatigue.Elevated levels of creatine kinase (relates to muscle problems).	None

PHARMACOKINETIC ENHANCERS (PK ENHANCERS)

GENERIC NAME	OTHER NAMES [BRAND NAME]*	DOSAGE (ADULTS)**	HOW TO TAKE	SIDE EFFECTS	CONTRAINDICATIONS
cobicistat	COBI [Tybost]	Prior to initiating therapy, assess estimated creatinine clearance. Take with atazanavir or darunavir: 150 mg by mouth daily, taken as (1) 150 mg tablet once daily	Take with food.	Jaundice, rash, nausea, diarrhea	Co-administration is contraindicated with certain drugs for which altered plasma concentrations are associated with serious and/or life-threatening events or loss of therapeutic effect.
ritonavir	RTV [Norvir]	1,200 mg by mouth daily, taken as (6) 100 mg tablets twice daily	Take with food.	Diarrhea, nausea, vomiting, abdominal pain, paresthesia and oral paresthesia, rash, fatigue/asthenia	Ritonavir is contraindicated in people with previous hypersensitivity reaction. Coadministration is contraindicated with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations may be associated with serious and/or life-threatening events. Coadministration is contraindicated with drugs that significantly reduce ritonavir.

COMBINATION HIV MEDICINES

abacavir dolutegravir lamivudine	[<u>Triumeq</u>]	Prior to initiating therapy, test for the HLA-B*5701 allele. 1 tablet by mouth once daily, containing 600 mg abacavir + 50 mg dolutegravir + 300 mg lamivudine	Take with or without food.	Insomnia, headaches, fatigue	Triumeq is contraindicated in people who have the HLA-B*5701 allele, people with previous hypersensitivity reaction to abacavir, dolutegravir, or lamivudine, people who also take dofetilide, and people who have moderate or severe hepatic impairment.
abacavir lamivudine	[Epzicom]	Prior to initiating therapy, test for the HLA-B*5701 allele. 1 tablet by mouth once daily, containing 600 mg abacavir + 300 mg lamivudine	Take with or without food.	Drug hypersensitivity, insomnia, depression/ depressed mood, headaches, fatigue, malaise, dizziness, vertigo, nausea, diarrhea	Epzicom is contraindicated in people who have the HLA-B*5701 allele, people with previous hypersensitivity reaction to abacavir or lamivudine, and people who have moderate or severe hepatic impairment.
atazanavir cobicistat	[Evotaz]	Prior to initiating therapy, test for renal and hepatic function. 1 tablet by mouth once daily, containing 300 mg atazanavir + 150 mg cobicistat	Take with food.	Jaundice, rash	Evotaz is contraindicated in people with previous hypersensitivity reaction to atazanavir or cobicistat.Co-administration is contraindicated with certain drugs for which altered plasma concentrations are associated with serious and/or life-threatening events or loss of therapeutic effect.

Prior to or when initiating B virus renal and hepatic function. 1 tablet by

bictegravir emtricitabine tenofovir AF

cabotegravir

rilpivirine

[Biktarvy]

therapy, test for hepatitis infection and mouth once daily, containing 50 mg bictegravir + 200 mg emtricitabine + 25 mg tenofovir AF

Take with or Diarrhea, without nausea, food. headaches Co-administration is contraindicated with dofetilide or rifampin.

Month 1: Oral lead-in

(1) 30 mg cabetogravir tablet by mouth daily, (1) 25 mg rilpivirine tablet by mouth dailyMonth 2: Initiation injections

1 intramuscular injection of 600 mg cabotegravir

+ 1 intramuscular Take oral injection of 900 mg rilpivirine [Cabenuva] monthly (administered are by a

healthcare provider) Month 3 onwards: Continuation injections

food.

intramuscular injection of 400 mg cabotegravir + 1 intramuscular injection of 600 mg rilpivirine monthly (administered by a healthcare provider)

lead-in Injection site tablets with reactions, fever, food. fatigue, Injections headaches, musculoskeletal administered pain, nausea, without sleep disorders, regard to dizziness, rash

Cabenuva is contraindicated in people with previous hypersensitivity reaction to cabotegravir or rilpivirine.Co-administration is contraindicated with drugs where significant decreases in cabotegravir and/or rilpivirine plasma concentrations may occur, which may result in loss of virologic response.

Prior to or when initiating therapy, test for HIV Co-administration is genotype and contraindicated with drugs Diarrhea, creatinine for which altered plasma nausea, rash, darunavir clearance. Take with concentrations are [Prezcobix] headaches, 1 tablet by associated with serious cobicistat food. abdominal pain, mouth once and/or life-threatening vomiting events or loss of daily, containing therapeutic effect. 800 mg darunavir + 150 mg cobicistat Prior to or when initiating therapy, test for hepatitis B virus Co-administration is infection and contraindicated with certain renal Diarrhea, rash, drugs for which altered function. darunavir nausea, fatigue, plasma concentrations are 1 tablet by cobicistat Take with headaches, associated with serious [Symtuza] mouth once emtricitabine food. abdominal and/or life-threatening daily, tenofovir AF discomfort, events or which may lead containing to loss of therapeutic effect flatulence 800 mg of Symtuza and darunavir + development of resistance. 150 mg cobicistat + 200 mg emtricitabine + 10 mg tenofovir AF

dolutegravir lamivudine

[Dovato]

when initiating therapy, test for hepatitis B virus infection and pregnancy in people of childbearing potential. 1 tablet by mouth once daily, containing 50 mg dolutegravir + 300 mg

lamivudine

Prior to or

Take with or without food.

Headaches, nausea, diarrhea, insomnia, fatigue, anxiety

Dovato is contraindicated in people with previous hypersensitivity reaction to dolutegravir or lamivudine.

dolutegravir rilpivirine	[Juluca]	Prior to or when initiating therapy, test for pregnancy in people of childbearing potential. 1 tablet by mouth once daily, containing 50 mg dolutegravir + 25 mg rilpivirine	Take with food.	Diarrhea, headaches	Juluca is contraindicated in people with previous hypersensitivity reaction to dolutegravir or rilpivirine, who also take dofetilide, and who also take drugs where significant decreases in rilpivirine plasma concentrations may occur, which may result in loss of virologic response.
		Prior to or			

doravirine lamivudinetenofovir DF

initiating therapy, test for hepatitis B virus infection and renal function. [Delstrigo] 1 tablet by

when

mouth once daily, containing 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir DF

Take with or without food.

Dizziness, nausea, abnormal dreams

Co-administration is contraindicated with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of Delstrigo.Delstrigo is contraindicated in people with previous hypersensitivity reaction to lamivudine.

efavirenz emtricitabine tenofovir DF

[Atripla]

when initiating therapy, test for hepatitis B virus infection, renal and hepatic function, and pregnancy in people of childbearing potential. 1 tablet by mouth once daily, containing

600 mg efavirenz + 200 mg emtricitabine + 300 mg tenofovir DF

Prior to or

Take on an empty stomach, preferably at bedtime.

Diarrhea, headaches, dizziness, depression, insomnia, abnormal

dreams, rash

nausea, fatigue, Atripla is contraindicated in people with previous hypersensitivity reaction to efavirenz and people who also take voriconazole or elbasvir/grazoprevir.

efavirenz lamivudine tenofovir DF

[Symfi, Symfi Lo] Prior to or when initiating therapy, test for hepatitis B virus infection and renal function.

1 tablet by mouth once daily, containing 600 mg efavirenz + 300 mg lamivudine + 300 mg tenofovir DF

Impaired concentration, abnormal dreams, headaches, nausea, malaise, preferably at signs and symptoms,

Take on an

empty

stomach,

bedtime.

fatigue, nasal diarrhea, rash, dizziness, insomnia, pain, depression, weakness, cough

Symfi is contraindicated in people with previous hypersensitivity reaction to efavirenz, lamivudine, or tenofovir DF, and people who also take elbasvir/grazoprevir.

elvitegravir cobicistat emtricitabine tenofovir AF

initiating therapy, test for hepatitis B virus infection and renal

Prior to or when

function. 1 tablet by

[Genvoya]

mouth once daily, containing 150 mg elvitegravir + 150 mg cobicistat + 200 mg emtricitabine + 10 mg tenofovir AF

Take with food.

Nausea, diarrhea, headaches, fatigue

Co-administration is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious adverse events.Coadministration is contraindicated with drugs that strongly induce CYP3A, which may lead to lower exposure of one or more components and loss of efficacy of Genvoya and possible resistance.

elvitegravir cobicistat emtricitabine tenofovir DF

[Stribild]

Prior to or when initiating therapy, test for hepatitis B virus infection and renal function.

1 tablet by mouth once daily, containing 150 mg elvitegravir + 150 mg cobicistat +

200 mg

emtricitabine + 300 mg tenofovir DF

Nausea, diarrhea, Take with abnormal food. dreams, headaches, fatigue, rash

Co-administration is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious adverse events.Coadministration is contraindicated with drugs that strongly induce CYP3A, which may lead to lower exposure of one or more components and loss of efficacy of Stribild and possible resistance.

Prior to or when initiating therapy, test for hepatitis B virus infection and renal function.

[Complera] 1 tablet by mouth once daily, containing 200 mg emtricitabine + 25 mg rilpivirine + 300 mg tenofovir DF

Take with

food.

Depressive disorders, insomnia. headaches, diarrhea, nausea, fatigue, dizziness, abnormal dreams, rash

Co-administration is contraindicated with drugs which may result in loss of virologic response and possible resistance to Complera.

emtricitabine rilpivirine tenofovir DF

HIV
treatment:
Prior to or
when
initiating
therapy, test
for hepatitis
B virus
infection and
renal
function.
HIV PrEP:
Prior to
initiating
therapy, test
for HIV
infection and
test again

emtricitabine tenofovir AF

[Descovy]

Take with or without food.

Diarrhea, nausea, headaches, fatigue, abdominal pain

Descovy for HIV PrEP is contraindicated in individuals with unknown or positive HIV status.

every 3
months while
taking and
upon
diagnosis of
any other
STIs
For both: 1
tablet by
mouth once
daily,
containing
200 mg
emtricitabine
+ 25 mg
tenofovir AF

HIV treatment: Prior to or when initiating therapy, test for hepatitis B virus infection and renal function. HIV PrEP: Diarrhea, Prior to initiating nausea, fatigue, therapy, test for HIV headaches, dizziness, Truvada for HIV PrEP is Take with or infection and emtricitabine depression, contraindicated in [<u>Truvada</u>] without tenofovir DF test again insomnia, individuals with unknown or food. every 3 months while positive HIV status. abnormal dreams, rash, abdominal pain, taking and upon weight loss diagnosis of any other STIs For both: 1 tablet by mouth once daily, containing 200 mg emtricitabine + 300 mg tenofovir DF

lamivudine tenofovir DF

[Cimduo]

Prior to or when initiating therapy, test for hepatitis B virus infection and renal function.

1 tablet by mouth once daily, containing 200 mg emtricitabine + 300 mg tenofovir DF

Take with or without food.

Headaches, pain, depression, diarrhea, rash Cimduo is contraindicated in people with previous hypersensitivity reaction to lamivudine or tenofovir DF.

lopinavir ritonavir [<u>Kaletra</u>]	800/200 mg by mouth daily, taken as (4) 200/50 mg tablets once daily OR (2) 200/50 mg tablets twice daily	Take tablets with or without food. Take oral solution with food.	nausea, vomiting,	Kaletra is contraindicated in people with previous hypersensitivity reaction to lopinavir or ritonavir.Co-administration is contraindicated with drugs where significant decreases in lopinavir plasma concentrations may occur, which may result in loss of virologic response and possible resistance and cross-resistance.

rilpivirine emtricitabine [<u>Odefsey</u>] tenofovir AF therapy, test for hepatitis B virus infection and renal function.

Prior to or when initiating

function.

1 tablet by
mouth once
daily,
containing
200 mg
emtricitabine
+ 25 mg
rilpivirine +
25 mg

tenofovir AF

Take with food.

Headaches, sleep disturbances Co-administration is contraindicated with drugs where significant decreases in rilpivirine plasma concentrations may occur, which may result in loss of virologic response and possible resistance and cross-resistance.

*Many of these medications are taken in combination with other ARVs. Talk with your healthcare provider about the treatment regimen that will work best for you.

**Dosages reflect normal use of each drug. However, ARVs are constantly being combined in new ways. Dosages may be higher or lower in the new combinations. Always talk with your healthcare provider before adjusting your medication dosages.

***NNRTIs and PIs are metabolized by the liver, as are many other drugs. Drug interactions can cause under doses that are ineffective or overdoses that can be fatal. Make sure your healthcare provider knows about all medications and supplements you are taking.

Reviewed March 2021